Introduction {#Sec1}
============

Febrile neutropenia (FN) is a serious side effect of many cancer treatments and can lead to infections and sepsis with potentially fatal consequences \[[@CR1]\]. The European Society of Medical Oncology defines FN as "an oral temperature of 38.3 °C or two consecutive readings of \> 38.0 °C for 2 hours and an absolute neutrophil count (ANC) of \< 0.5 × 10^9^/L, or expected to fall below \< 0.5 × 10^9^/L" \[[@CR2]\]. The Infectious Diseases Society of America defines it as an "ANC \< 500 cells/mm^3^ (or that is expected to decrease to \< 500 cells/mm^3^ during the next 48 hours) with a single oral temperature measurement of \> 38.3 °C or a temperature of ≥ 38.0 °C sustained over a 1-hour period" \[[@CR3]\]. In patients receiving chemotherapy, development of FN can result in dose reduction and/or treatment delays, or treatment discontinuation, which may limit disease control \[[@CR1], [@CR4]\].

The overall global incidence of FN is difficult to assess as events are not always identified or reported. Neutropenic hospitalizations, frequently associated with FN, are simpler to quantify. US studies suggest an estimated 7.83 neutropenic hospitalizations per 1000 cancer patients each year (60,294 cases in 1999), with incidence increasing to 43.3 cases per 1000 patients in those with hematologic malignancies \[[@CR5]\]. Evidence from clinical trials and clinical practice suggests the incidence of FN may be higher (up to 117 cases per 1000 patients) \[[@CR6], [@CR7]\].

Current guidelines recommend granulocyte colony-stimulating factors (G-CSF) for primary prophylaxis of chemotherapy-induced FN when the overall risk of FN among patients with non-myeloid malignancies receiving myelosuppressive chemotherapy is ≥ 20% \[[@CR1], [@CR2], [@CR8]\]. In clinical trials and daily practice, primary and secondary prophylaxis with G-CSF has been shown to reduce FN incidence and complications and improve outcomes of cancer treatment \[[@CR1], [@CR9]\]. However, despite guideline recommendations, G-CSF primary prophylaxis remains underutilized in clinical practice \[[@CR10], [@CR11]\] and patients often receive inconsistent and suboptimal courses of G-CSF treatment \[[@CR12], [@CR13]\].

The majority of available G-CSF treatments are short-acting; however, the number of long-acting agents (e.g., pegfilgrastim and lipegfilgrastim) is increasing. Pegfilgrastim is the most widely approved long-acting G-CSF available worldwide. Initially approved in 2002, it is now the most commonly used and is associated with the most experience and clinical data. Lipegfilgrastim, which was approved in 2013, has more limited availability worldwide (primarily available in Europe) and, thus, there is less experience of its use \[[@CR14], [@CR15]\]. In clinical trials and practice, pegfilgrastim has been shown to have a favorable efficacy and safety profile \[[@CR14], [@CR16]--[@CR20]\] and may be preferred over short-acting G-CSF by both patients and physicians due to improved adherence and its convenient once-per-cycle subcutaneous administration.

Biosimilar products are biologic medicines that have highly similar physicochemical and functional characteristics; they must demonstrate a similar quality, efficacy, and safety profile to the reference biologic product \[[@CR21]\]. G-CSF biosimilars are increasingly being used for prevention of chemotherapy-induced FN \[[@CR22]--[@CR24]\].

While current guidelines provide general recommendations on the use of G-CSF for prevention of chemotherapy-induced FN, they do not distinguish between the use of pegfilgrastim/lipegfilgrastim and short-acting G-CSF in practice, nor do they provide guidance on the most appropriate patient profile for each agent. Guidance on the appropriate use of pegfilgrastim in particular situations and patient populations does not exist.

In November 2015, a group of experts in the management of chemotherapy-induced FN, with experience in solid tumors and hematologic malignancies, convened to develop a consensus document to direct the appropriate use of pegfilgrastim in clinical practice. The aim was to establish clear guidance recommendations on the appropriate use of pegfilgrastim for prevention of chemotherapy-induced FN, considering different situations and patient populations encountered in clinical practice. This document is intended to complement the information provided in existing guidelines and provide clinically relevant suggestions for use in daily practice.

Methods {#Sec2}
=======

Expert selection {#Sec3}
----------------

Experts were selected for participation in the advisory board if they were a specialist in oncology and/or onco-hematology and had extensive clinical experience with both short-acting and long-acting G-CSF. They were also required to be involved in clinical research and academic work in chemotherapy-induced FN and in generating publications in this field. They were also required to be fluent English speakers.

Literature review {#Sec4}
-----------------

Ahead of the guidance group meeting, a literature review (details provided in Table [1](#Tab1){ref-type="table"}) was performed to establish the current evidence base on the use of pegfilgrastim and identify key areas in which data and guidance are lacking or areas of inconsistency within these. This broad review was undertaken before development of the consensus statements. The search terms used for this literature search were \["neutropenia" AND "chemotherapy" AND ("long-acting G-CSF" OR pegfilgrastim OR peg-filgrastim OR "pegylated G-CSF" OR biosimilar OR Neulasta OR "LA EP 2006" OR Lonquex OR lipegfilgrastim OR ristempa OR neupeg OR pegasta OR neulastim OR coherus OR apotex OR apotes OR "mylan peg-filgrastim")\] and \["neutropenia" AND "chemotherapy" AND "long-acting" AND "colony stimulating factor"\].Table 1Literature review exclusion criteriaExclusion criteriaNumber excludedPublished in 1999 or earlier2Studies in non-human animals/in vitro/ex vivo12Studies in children/adolescents15Does not include long-acting G-CSF89Not receiving G-CSF for prophylaxis/treatment of chemotherapy-induced FN during cancer treatment47Not trial data, letter to editor, or case study142Does not contribute to research question: "In which circumstances is long-acting G-CSF (pegfilgrastim) efficacious for prevention of chemotherapy-induced FN in individuals diagnosed with cancer?"60Not phase II--IV RCTs, prospective non-randomized studies, letters to editor or case studies34Cannot be accessed1The final literature search was performed on 17 November 2015, ahead of the guidance group meeting. To capture all phase II--IV trials with pegfilgrastim reference product, "1999" was selected as a cutoff for relevant publications; publications prior to this date would not be relevant*FN* febrile neutropenia, *G-CSF* granulocyte colony-stimulating factor, *RCT* randomized controlled trial

A total of 446 unique references were identified from PubMed Central and the Cochrane database, providing data on the current use of pegfilgrastim. References were selected for review using the exclusion criteria detailed in Table [1](#Tab1){ref-type="table"}. In all, 44 unique references were included in the final list and used to support development of the guidance recommendations in this publication.

Development of guidance recommendations {#Sec5}
---------------------------------------

The guidance recommendations included in this publication are intended to fill the gaps identified in the current guidelines and were established based on findings from the literature review, as well as the experts' experience and opinions. An electronic survey and a subsequent consensus meeting were held to determine the wording and supporting content. Consensus was established using a Delphi-based method (Table [2](#Tab2){ref-type="table"}), which is a well-established, structured, and systematic method of gaining consensus using a panel of experts \[[@CR25]\].Table 2Delphi-based consensus criteriaConsensus reached≥ 75% vote "agree" or "strongly agree"Group recommendation≥ 50% vote "agree" or "strongly agree"Further evidence required\< 50% vote "agree" or "strongly agree"Twelve advisors provided their response to the electronic survey and 11 participated and voted during the consensus meeting; one advisor did not respond to the survey but attended the consensus meeting; and two responded to the survey but did not attend the consensus meeting. All advisors are listed as authors on this paper. In the survey and meeting, consensus was reached if nine or more advisors voted "agree" or "strongly agree." Consensus was reached on three guidance recommendations through the electronic survey; the remaining statements were confirmed during the consensus meeting. A total of 19 proposed statements were discussed during this meeting. The structure of these discussions is detailed in the "[Methods](#Sec2){ref-type="sec"}" section

The Delphi-based method was performed as follows:First, the authors voted on their agreement with suggested consensus guidance statements via an anonymous electronic survey. Statements on which consensus was not reached were refined and adapted based on literature search findings and expert opinion.The authors then discussed the updated statements at an interactive consensus meeting and refined the statements as required.The authors voted anonymously on their agreement with the updated consensus guidance statements. If consensus could not be reached, there was further discussion on the relevant statement; the authors provided their rationale for agreement or disagreement with the proposed statement and it was refined further if necessary.The authors then voted anonymously on their agreement with the final statement. If consensus was reached, the statement was included in this publication. If consensus was not reached, a recommendation was not made; however, relevant information relating to such statements is included where appropriate.

Results {#Sec6}
=======

Guidance recommendations {#Sec7}
------------------------

Consensus was reached on all guidance recommendations listed in this publication. The level (strength) of evidence for each recommendation was evaluated in line with widely used grading criteria \[[@CR1]\]:I.Evidence obtained from meta-analysis of multiple, well-designed, controlled studies or from high-power randomized, controlled clinical trialsII.Evidence obtained from at least one well-designed experimental study or low-power randomized, controlled clinical trialIII.Evidence obtained from well-designed, quasi-experimental studies such as non-randomized, controlled single-group, pre-post, cohort, time, or matched case-control studiesIV.Studies such as comparative and correlational descriptive and case studiesV.Evidence obtained from case reports and clinical examples

The European Organisation for Research and Treatment of Cancer guidelines were used as a source document for grading recommendations.

General statements and recommendations {#Sec8}
--------------------------------------

*Prevention of chemotherapy-associated FN is not yet optimal* (consensus reached (83%); evidence level II).

Prevention and treatment of chemotherapy-induced FN using G-CSF in clinical practice may often deviate from clinical guidelines \[[@CR12], [@CR26]\]. Furthermore, no clinical guidelines are available to support use of G-CSF in some situations, for example during the use of targeted cancer treatments. Studies suggest that the high-risk patients who require G-CSF treatment are often undertreated, with only 17% receiving appropriate G-CSF treatment \[[@CR27]\].

*When cure is the intention of chemotherapy, maintenance of planned dose intensity using G-CSF to prevent dose delays or dose reductions should be the standard of care* (consensus reached (100%); evidence level I).

In patients receiving chemotherapy or targeted treatments with curative intent, delays or dose reductions in chemotherapy can have a significant impact on the efficacy of treatment and can therefore impact patient survival \[[@CR1], [@CR4], [@CR28]\]. It is our opinion that treatment delays due to avoidable circumstances such as FN should be prevented where possible. Routine use of short- or long-acting G-CSF is an established method for prophylaxis of FN \[[@CR1], [@CR2], [@CR8]\].

Recommendations according to risk of FN {#Sec9}
---------------------------------------

*In patients receiving chemotherapy and/or targeted agents with a FN risk ≥ 20%, pegfilgrastim or short-acting G-CSF should be given from cycle 1 throughout all cycles of chemotherapy* (consensus reached (100%); evidence level I).

*In patients receiving chemotherapy and/or targeted therapy with a FN risk 10--20%, if factors that increase this risk (see* *Table* [*3*](#Tab3){ref-type="table"} *) suggest that the overall risk of neutropenia-related complications is ≥ 20%, the patient should receive pegfilgrastim or short-acting G-CSF* (consensus reached (100%); evidence level V).Table 3Factors possibly associated with elevating FN risk which should be considered when estimating the overall risk of FN \[[@CR29]\]Age \>65 yearsLow performance status (low Karnofsky index, high ECOG score)Comorbidities, including COPD, heart failure (NYHA III--IV), HIV infection, autoimmune disease, marked renal impairmentSignificantly advanced, symptomatic tumor diseasePrior chemotherapyLaboratory parameters, including anemia, lymphocytopenia (\< 700 cells/μl), hyperalbuminuria, hyperbilirubinemiaThis table is based on the German G-CSF guidelines group consensus statement \[[@CR29]\]. All factors listed in this table are likely to increase the risk of FN, particularly when present in combination. Many other comorbidities have been linked with a possible increase in the risk of FN, but their associated risks have not been definitively proven. These factors should be considered when estimating the overall risk of FN*COPD* chronic obstructive pulmonary disease, *ECOG* Eastern Cooperative Oncology Group, *FN* febrile neutropenia, *G-CSF* granulocyte colony-stimulating factor, *HIV* human immunodeficiency virus, *NYHA* New York Heart Association

*In patients receiving chemotherapy and/or targeted therapy even with a FN risk \< 10%, if special factors suggest that the overall risk of neutropenia-related complications is ≥ 20% (see Table* [*3*](#Tab3){ref-type="table"} *), the patient should receive pegfilgrastim or short-acting G-CSF* (consensus reached (100%); evidence level V).

The decision to prescribe G-CSF should always be a joint decision between the patient and the treating physician. In patients with a treatment-associated FN risk of \< 20%, this group believes it is critical to consider other factors that may increase the risk of FN or result in poorer outcomes should it develop.

Patient-, disease-, and treatment-related factors should be considered and G-CSF should not be denied to a patient solely on the basis of treatment-related FN risk. Table [3](#Tab3){ref-type="table"} details factors that should be considered when assessing the risk of FN or associated negative outcomes. Once initiated, G-CSF should be continued through all cycles of chemotherapy \[[@CR8]\]. More specific recommendations for patients with hematologic malignancies are listed later in this publication.

Use of pegfilgrastim vs short-acting G-CSF {#Sec10}
------------------------------------------

*Clinical trial data suggest a similar efficacy and safety profile with pegfilgrastim and 11 days' filgrastim.* [1](#Fn1){ref-type="fn"} *If 11 days' filgrastim is not utilized, pegfilgrastim should be given in preference to a reduced duration of daily filgrastim* (consensus reached (91%); evidence level I).

A similar efficacy and safety profile has been seen in individual studies comparing an average of 11 days' filgrastim treatment with pegfilgrastim \[[@CR30]--[@CR35]\], and meta-analyses suggest that, overall, pegfilgrastim may be more efficacious than filgrastim \[[@CR37], [@CR38]\] (Fig. [1](#Fig1){ref-type="fig"}). Across studies, the efficacy benefits demonstrated include a reduction in incidence of FN, a reduction in FN-related hospitalizations, and improved time to ANC recovery with pegfilgrastim vs filgrastim \[[@CR37]--[@CR39]\]. These findings are also supported by data from clinical practice \[[@CR40]--[@CR43]\].Fig. 1Incidence of FN in Clinical Trials. *Superscript a*: FN all cycles. *Superscript b*: FN ≥ 1 cycle. *Superscript c*: FN cycles 1 and 2. *CI* confidence interval, *FN* febrile neutropenia, *RR* risk ratio \[[@CR30]--[@CR34], [@CR38]\]

In clinical practice, duration of filgrastim treatment is routinely shorter than 11 days and often shorter than 7 days \[[@CR40], [@CR41], [@CR43]--[@CR45]\]. It is not clear whether a reduced duration of filgrastim could achieve similar efficacy and safety benefits to pegfilgrastim or 11 days' filgrastim. Furthermore, these data suggest a reduced duration of filgrastim may be associated with worse outcomes compared with 11 days' filgrastim or pegfilgrastim \[[@CR13], [@CR36], [@CR46]\]. As such, it is our opinion that pegfilgrastim may be preferable to filgrastim in clinical practice, particularly if there is a risk that filgrastim will not be continued for at least 11 days. If filgrastim is used, it should be maintained until the neutropenia has passed and neutrophil count has returned to normal, which may take up to 14 days \[[@CR47], [@CR48]\].

*Based on the convenience and patient adherence, pegfilgrastim may be preferred to 11 days' filgrastim for prevention of chemotherapy-induced FN. This is particularly the case in frail or elderly patients* (consensus reached (100%); evidence level V).

In clinical practice, patients rarely receive the full dose of filgrastim, partially due to limitations with perceived patient adherence and convenience \[[@CR13], [@CR36], [@CR42], [@CR49], [@CR50]\]. While daily administration of filgrastim is required, pegfilgrastim (reference product and biosimilar) is a single once-per-cycle injection \[[@CR14]\]. Once-per-cycle dosing may be more convenient for patients, as there is no requirement for daily self-administration, hospital visits, or regular tests to evaluate ANC levels. It was suggested by the group that this may be associated with increased treatment adherence from patients, thus favoring the use of pegfilgrastim over filgrastim; however, this has not been thoroughly investigated in randomized controlled studies.

Use of pegfilgrastim vs short-acting G-CSF---additional topics of interest {#Sec11}
--------------------------------------------------------------------------

This group could reach no clear consensus on whether pegfilgrastim or filgrastim is more appropriate for patients who experience bone pain. In patients who experience bone pain or other G-CSF-related side effects, consider switching from filgrastim to pegfilgrastim or vice versa. Based on very limited data, it may also be possible to reduce the dose of pegfilgrastim treatment \[[@CR51]\]; although, this represents off-label use and the effectiveness of this approach is disputed. As such, reducing the dose of pegfilgrastim is not recommended.

No clear consensus was reached on the optimal use of pegfilgrastim in patients with renal impairment. The opinion of this group is that no dose reduction is required in these patients, as pegfilgrastim is neutrophil-eliminated rather than renally eliminated, and studies suggest renal dysfunction has no effect on the pharmacokinetics of this agent \[[@CR14]\].

Recommendations according to treatment type {#Sec12}
-------------------------------------------

*In the absence of evidence from clinical trials, pegfilgrastim is not appropriate in patients receiving weekly chemotherapy* (consensus reached (100%); evidence level V).

Weekly chemotherapy regimens are becoming increasingly common, particularly with agents including taxanes, gemcitabine, and vinorelbine; however, data on the use of pegfilgrastim with weekly chemotherapy regimens are limited. One prospective, non-randomized study (*n* = 24) has demonstrated positive outcomes with pegfilgrastim administered on a fortnightly schedule, on the same day as chemotherapy, in patients receiving weekly chemotherapy \[[@CR52]\], suggesting its use may be possible in these patients. At the current time, however, our opinion is that short-acting G-CSF may be more appropriate until further evidence is available.

Pegfilgrastim has been used effectively in patients receiving fortnightly chemotherapy regimens (R-CHOP-14); in this instance, the other recommendations detailed in this publication apply \[[@CR53]\].

*In patients receiving split-dose chemotherapy, pegfilgrastim administration is recommended 24 h after the last chemotherapy dose* (consensus reached (100%); evidence level II).

In split-dose regimens, chemotherapy treatment may be administered on multiple days throughout one chemotherapy cycle. Administration of pegfilgrastim is recommended ≥ 24 h after the last chemotherapy dose and ≥ 14 days before the next dose. Two studies have demonstrated positive outcomes with this approach, though data are limited \[[@CR54], [@CR55]\]. In clinical practice, this is considered a well-established and appropriate approach for use of pegfilgrastim in patients receiving split-dose chemotherapy.

*If a need for G-CSF has been identified for maintenance of treatment dose or prevention of chemotherapy-induced FN in patients receiving palliative treatment, the issues of convenience and adherence may favor use of pegfilgrastim. Dose reductions or change in chemotherapy regimen should also be considered* (consensus reached (100%); evidence level V).

Although treatment delays and dose reductions may be less concerning in patients receiving palliative treatment, G-CSF may be required in high-risk patients to avoid the serious and even life-threatening complications associated with FN. Furthermore, maintenance of dose intensity can be associated with significant survival benefits in patients receiving palliative treatment \[[@CR56], [@CR57]\].

In patients receiving palliative care requiring G-CSF treatment, guidance recommendations discussed in this publication apply. When possible, switching to an alternate treatment, reducing treatment dose, or providing larger breaks between treatment cycles may be considered in preference, or in addition, to use of G-CSF.

*Once initiated, pegfilgrastim prophylaxis should be continued throughout all cycles of chemotherapy* (consensus reached (100%); evidence level II).

When pegfilgrastim prophylaxis is discontinued, the risk of FN increases in the subsequent chemotherapy cycle; if pegfilgrastim is continued throughout treatment, a consistently low risk of FN is maintained \[[@CR58]\]. This group suggests that the perceived convenience and patient adherence benefits associated with pegfilgrastim vs filgrastim may favor consistent use throughout treatment.

*In this new era of targeted and immunotherapies, additional trials with G-CSF are required* (consensus reached (100%); evidence level V).

There are limited data on the use of G-CSF for prevention of FN induced by targeted agents and immunotherapies. Targeted agents with various mechanisms of action, including immunomodulatory agents (e.g., lenalidomide, pomalidomide), proteasome inhibitors (e.g., bortezomib, carfilzomib), monoclonal antibodies (e.g., obinutuzumab, brentuximab vedotin), and B cell receptor inhibitors (e.g., ibrutinib, idelalisib), may be associated with neutropenia, though the incidence of FN is variable \[[@CR59]--[@CR64]\]. In the absence of specific guidance on use of G-CSF with these agents, the guidance recommendations for chemotherapy in this publication should be applied.

Special considerations for patients with hematologic malignancies {#Sec13}
-----------------------------------------------------------------

*In patients with multiple myeloma (MM) needing G-CSF, pegfilgrastim can be given in some instances, but filgrastim may have more applications given some current regimens and can be given concurrently with some treatment regimens (e.g., immunomodulatory drugs and proteasome inhibitors)* (consensus reached (100%); evidence level V).

There are limited studies with pegfilgrastim in patients with MM. Many patients are ≥ 65 years old with a high risk of FN and therefore require G-CSF treatment, although risk of FN is regimen dependent. MM guidelines recommend use of a G-CSF to allow optimal duration of active therapy; this should be initiated if grade 4 neutropenia (uncomplicated) or grade 3 neutropenia (with infection) occurs and continued until disease progression or toxicity is encountered \[[@CR65], [@CR66]\]. Primary G-CSF prophylaxis is recommended when the rate of grade 3 or 4 neutropenia is expected to be \> 50% and with low or intermediate risk regimens when tumor- or patient-related risk factors are present and ANC is \< 1000 cells/mL at the start of chemotherapy \[[@CR66]\].

Weekly and fortnightly chemotherapy regimens are more frequent in treatment of MM, which may result in a greater role for filgrastim than pegfilgrastim. Risk of FN is less clear with non-chemotherapy regimens; the most appropriate choice of G-CSF with some agents (e.g., immunomodulatory drugs and proteasome inhibitors) has not yet been determined.

*In newly diagnosed patients with acute myeloid leukemia (AML) receiving induction therapy, filgrastim could be considered. In patients receiving consolidation chemotherapy with curative intent, pegfilgrastim may be preferred to filgrastim* (consensus reached (100%); evidence level II).

There are limited studies with pegfilgrastim in patients with AML and its long-term effects have not been established. Although data are emerging, there is currently no strong evidence to support its use in this patient population \[[@CR14], [@CR67]--[@CR70]\].

Pegfilgrastim cannot be recommended during induction therapy and is contraindicated in patients with chronic myeloid leukemia \[[@CR14]\].

*In patients with lymphoma/chronic lymphocytic leukemia, or MM receiving targeted treatments, pegfilgrastim or short-acting G-CSF can be considered if needed to continue treatment* (consensus reached (100%); evidence level IV).

There are limited data on the use of G-CSF for prevention of FN induced by targeted agents and immunotherapies, although many targeted agents have an associated FN risk (please refer to earlier recommendations). G-CSF support should be considered if grade ≥ 3 neutropenia occurs, and its use is recommended in the Summary of Product Characteristics for some targeted agents \[[@CR59], [@CR60]\].

Additional topics of interest {#Sec14}
-----------------------------

Lipegfilgrastim, a long-acting filgrastim approved by the EMA, has been shown to have a similar efficacy and safety profile vs pegfilgrastim for prophylaxis of chemotherapy-associated FN. Two pivotal studies, and one dose-finding study, provided direct evidence for the effectiveness of lipegfilgrastim prophylaxis vs pegfilgrastim prophylaxis \[[@CR15], [@CR71]--[@CR73]\].

Lipegfilgrastim is primarily available in Europe but has limited availability worldwide compared with pegfilgrastim. It should be noted that no specific recommendations have been made on the most appropriate use of lipegfilgrastim in this publication, as lipegfilgrastim data were not considered during the guidance group meeting and as such did not influence the guidance recommendations agreed.

Discussion {#Sec15}
==========

FN is a serious side effect of many cancer treatments and can lead to severe infection and sepsis with potentially fatal consequences \[[@CR1]\]. G-CSF, including pegfilgrastim, are recommended for primary and secondary prophylaxis of chemotherapy-induced FN and have demonstrated efficacy in clinical trials and daily practice \[[@CR1], [@CR2], [@CR9]\]. Pegfilgrastim is the only long-acting G-CSF available worldwide and is associated with the most clinical data and experience. The guidance statements are not absolute recommendations but are intended as a guide for the clinician in daily clinical practice; they should be used alongside current guidelines. The expert panel suggests that the guidance statements in this publication should be used in parallel with existing guidelines to optimize the appropriate use of G-CSF and of pegfilgrastim in cancer patients in clinical practice.

Average duration of filgrastim treatment was 11 days in clinical trials of filgrastim vs pegfilgrastim \[[@CR30]--[@CR36]\].
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